The Scion announced that results from a randomized, controlled trial of Parkinson’s disease (PD) subjects who used company’s non-invasive neuromodulation device TNM™ has been published.
The TNM™ device is non-invasive and can be used at home conveniently. It is used to directly stimulates the vestibular system, a sensory network with strong and diffuse pathways throughout the brain.
The TNM™ device was used by the patients for 2 months after the pre-treatment baseline assessment period and then they were re-assessed. The results showed that the device could be used adjunctly to current standard of care PD therapy. The therapy using this device also showed the potential to address multiple motor and non-motor PD symptoms.
For the prevention of episodic migraine, TNM™ Device 3.2 has been granted US market entry (for adults and adolescents ages 12 and older) and CE marked in the EU market (for adults). An FDA-designated breakthrough device, TNM™ Device 4.0, can only be used in the setting of a clinical trial because it is limited by U.S. Law to Investigational Use.
Clinical Research Newsletter
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like